Antipsychotics

**

Overview

Antipsychotics, historically called neuroleptics or major tranquilizers, act on brain neurotransmitter systems—most notably dopamine—to reduce the intensity of psychotic experiences. They are divided into first‑generation (typical) agents, which mainly block dopamine D₂ receptors, and second‑generation (atypical) agents, which combine dopamine antagonism with serotonin (5‑HT₂A) modulation and often have a broader side‑effect profile. Clinicians prescribe these medications to manage schizophrenia, schizoaffective disorder, bipolar mania, and as adjuncts in treatment‑resistant major depressive disorder. While they can dramatically improve quality of life, antipsychotics also carry risks such as metabolic syndrome, extrapyramidal symptoms, and tardive dyskinesia; therefore, regular monitoring and dose adjustments are crucial. If you or someone you know experiences new or worsening symptoms while taking an antipsychotic, seek professional medical advice promptly.

History/Background

The modern era of antipsychotic therapy began in the early 1950s with the discovery of chlorpromazine (Thorazine) by French chemist Paul Charpentier and its psychiatric application by Henri Guy. Chlorpromazine’s calming effect on hospitalized patients marked the first successful pharmacologic treatment for schizophrenia, ushering in the “chemical revolution” in psychiatry. Throughout the 1960s and 1970s, other typical agents such as haloperidol, fluphenazine, and perphenazine entered the market, solidifying dopamine blockade as the core mechanism. Dissatisfaction with severe motor side effects spurred the development of atypical agents in the 1990s; clozapine (approved 1990) demonstrated efficacy in treatment‑resistant schizophrenia but required blood‑monitoring for agranulocytosis. Subsequent atypicals—risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone—offered improved tolerability and broadened indications, including bipolar disorder and adjunctive depression therapy.

Key Information

- Mechanism of Action: Typical antipsychotics are high‑affinity D₂ antagonists; atypicals add 5‑HT₂A antagonism, partial D₂ agonism (e.g., aripiprazole), or other receptor effects. - Classification: - First‑generation (typical): chlorpromazine, haloperidol, fluphenazine. - Second‑generation (atypical): clozapine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, lurasidone. - Indications: Schizophrenia, schizoaffective disorder, bipolar I mania, bipolar depression (as adjunct), treatment‑resistant major depressive disorder, Tourette syndrome, and certain agitation states. - Common Side Effects: - Typical: Extrapyramidal symptoms (EPS), tardive dyskinesia, hyperprolactinemia. - Atypical: Weight gain, dyslipidemia, diabetes risk, sedation, orthostatic hypotension. - Monitoring Requirements: Baseline and periodic metabolic panels, fasting glucose, lipid profile, weight/BMI, and for clozapine, absolute neutrophil count (ANC) weekly to monthly. - Drug Interactions: Antipsychotics can interact with CYP450 substrates, anticholinergics, and QT‑prolonging agents; clinicians must review concomitant medications. - Pregnancy & Lactation: Data are limited; risk‑benefit assessment is essential, and many guidelines advise using the lowest effective dose under specialist supervision.

Significance

Antipsychotics transformed mental health care by providing a pharmacologic alternative to long‑term institutionalization, enabling many individuals to live independently, pursue education, and maintain employment. Their introduction reduced global psychiatric bed occupancy and shifted treatment paradigms toward community‑based care. Moreover, the development of atypical agents broadened therapeutic horizons, allowing clinicians to address mood symptoms and reduce motor side effects, which improved adherence and long‑term outcomes. Ongoing research into novel mechanisms—such as glutamate modulation, phosphodiesterase inhibition, and neuroinflammation—promises the next generation of antipsychotics with fewer metabolic complications. Nonetheless, the class remains a double‑edged sword: while life‑changing for many, it demands vigilant medical oversight to balance efficacy with safety. Patients should never adjust or discontinue antipsychotic therapy without consulting a qualified health professional, as abrupt changes can precipitate relapse or severe withdrawal phenomena.

INFOBOX:
- Name: Antipsychotics (Neuroleptics, Major Tranquilizers)
- Type: Psychotropic medication class
- Date: First marketed 1952 (chlorpromazine)
- Location: Worldwide clinical use
- Known For: Managing schizophrenia, bipolar disorder, and adjunctive treatment of resistant depression

TAGS: schizophrenia, bipolar disorder, psychopharmacology, dopamine antagonists, atypical antipsychotics, mental health, psychiatric medication, treatment‑resistant depression